142 related articles for article (PubMed ID: 9067410)
1. Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma.
Takeuchi T; Ueki T; Sasaki Y; Kajiwara T; Li B; Moriyama N; Kawabe K
Cancer Immunol Immunother; 1997 Jan; 43(6):375-81. PubMed ID: 9067410
[TBL] [Abstract][Full Text] [Related]
2. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T
BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-2 blocks the antitumour activity caused by depletion of CD25 cells in a murine renal adenocarcinoma model.
Takeuchi T; Konno-Takahashi N; Kasuya Y; Ogushi T; Nishimatsu H; Kitamura T
BJU Int; 2004 Jul; 94(1):171-6. PubMed ID: 15217455
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
[TBL] [Abstract][Full Text] [Related]
5. Trafficking of 'immune' CD4(+)/CD8(+)T-lymphocytes into the RENCA tumour microcirculation in vivo in mice.
Ali SA; Rees RC; Anderson DQ; Reed MW; Goepel JR; Brown NJ
Br J Cancer; 2000 Oct; 83(8):1061-8. PubMed ID: 10993655
[TBL] [Abstract][Full Text] [Related]
6. CD95 ligand expression enhances growth of murine renal cell carcinoma in vivo.
Nishimatsu H; Takeuchi T; Ueki T; Kajiwara T; Moriyama N; Ishida T; Li B; Kakizoe T; Kitamura T
Cancer Immunol Immunother; 1999 Apr; 48(1):56-61. PubMed ID: 10235489
[TBL] [Abstract][Full Text] [Related]
7. Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages.
Fan K; Zhou M; Pathak MK; Lindner DJ; Altuntas CZ; Tuohy VK; Borden EC; Yi T
J Immunol; 2005 Nov; 175(10):7003-8. PubMed ID: 16272361
[TBL] [Abstract][Full Text] [Related]
8. T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma.
Harada M; Iida Y; Kotani H; Minami T; Komohara Y; Eto M; Yoshikawa K; Uemura H
Cancer Immunol Immunother; 2022 Feb; 71(2):339-352. PubMed ID: 34160685
[TBL] [Abstract][Full Text] [Related]
9. Effects of stimulating interleukin -2/anti- interleukin -2 antibody complexes on renal cell carcinoma.
Han KH; Kim KW; Yan JJ; Lee JG; Lee EM; Han M; Cho EJ; Kang SS; Lim HJ; Koo TY; Ahn C; Yang J
BMC Urol; 2016 Jan; 16():2. PubMed ID: 26772545
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity.
Saffran DC; Horton HM; Yankauckas MA; Anderson D; Barnhart KM; Abai AM; Hobart P; Manthorpe M; Norman JA; Parker SE
Cancer Gene Ther; 1998; 5(5):321-30. PubMed ID: 9824052
[TBL] [Abstract][Full Text] [Related]
12. Rejection of mouse renal cell carcinoma elicited by local secretion of interleukin-2.
Hara I; Hotta H; Sato N; Eto H; Arakawa S; Kamidono S
Jpn J Cancer Res; 1996 Jul; 87(7):724-9. PubMed ID: 8698622
[TBL] [Abstract][Full Text] [Related]
13. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.
Wysocki PJ; Kazimierczak U; Suchorska W; Kotlarski M; Malicki J; Mackiewicz A
Cancer Gene Ther; 2010 Jul; 17(7):465-75. PubMed ID: 20168352
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration.
Hara I; Nagai H; Miyake H; Yamanaka K; Hara S; Micallef MJ; Kurimoto M; Gohji K; Arakawa S; Ichihashi M; Kamidono S
Cancer Gene Ther; 2000 Jan; 7(1):83-90. PubMed ID: 10678360
[TBL] [Abstract][Full Text] [Related]
15. Hyper-interleukin-11 novel designer molecular adjuvant targeting gp130 for whole cell cancer vaccines.
Suchorska WM; Dams-Kozlowska H; Kazimierczak U; Wysocki PJ; Mackiewicz A
Expert Opin Biol Ther; 2011 Dec; 11(12):1555-67. PubMed ID: 21995459
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors.
Søndergaard H; Frederiksen KS; Thygesen P; Galsgaard ED; Skak K; Kristjansen PE; Odum N; Kragh M
Cancer Immunol Immunother; 2007 Sep; 56(9):1417-28. PubMed ID: 17285290
[TBL] [Abstract][Full Text] [Related]
17. Transfer of IFNgamma-depleted CD4(+) T cells together with CD8(+) T cells leads to rejection of murine kidney sarcoma in mice.
Klugewitz K; Scheffold A; Radbruch A; Hamann A
Int J Cancer; 2000 Sep; 87(5):673-9. PubMed ID: 10925361
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity.
Mendiratta SK; Quezada A; Matar M; Wang J; Hebel HL; Long S; Nordstrom JL; Pericle F
Gene Ther; 1999 May; 6(5):833-9. PubMed ID: 10505108
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
20. Application of cytokine drug delivery systems to the immunotherapy of renal cell carcinoma in mice.
Marumo K; Oya M; Murai M; Tazaki H
Int J Urol; 1996 Jan; 3(1 Suppl):S24-7. PubMed ID: 24304015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]